Anti-TIF1-γ antibody and cancer-associated myositis
| Autor: | Takashi Mikata, Takayuki Momoo, Nobue K. Iwata, Yuki Hatanaka, Ran Nakashima, Kazuhiro Ito, Shoji Tsuji, Yoshio Sakiyama, Takenari Yamashita, Yusuke Miwa, Masahiro Sonoo, Yasufumi Motoyoshi, Yoshikazu Uesaka, Yasuhisa Sakurai, Shin Kwak, Yasushi Shiio, Jun Shimizu, Masato Kadoya, Kenichi Kaida, Satoko Arai, Atsuro Chiba, Tomoko Iwanami, Aya Oda, Naoki Masuda, Hiroyuki Shimada, Yuji Hosono, Kiyoharu Inoue, Sousuke Takeuchi, Kazuhiro Kurasawa, Ayumi Hida, Manami Inoue, Hideji Hashida, Tsuneyo Mimori, Ayumi Uchibori, Reika Maezawa, Shigeo Murayama, Meiko Hashimoto Maeda, Hitoshi Aizawa, Nobuyuki Yajima, Toshihiro Yoshizawa, Yoshiharu Nakae, Hidetoshi Date |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty animal structures Disease Vacuolated fibers Gastroenterology 03 medical and health sciences 0302 clinical medicine Atrophy Neoplasms Internal medicine Biopsy medicine Humans Myositis Autoantibodies Retrospective Studies 030203 arthritis & rheumatology biology medicine.diagnostic_test business.industry Nuclear Proteins Cancer Dermatomyositis medicine.disease biology.protein Female Neurology (clinical) Antibody Apoptosis Regulatory Proteins business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Neurology. 87:299-308 |
| ISSN: | 1526-632X 0028-3878 |
| DOI: | 10.1212/wnl.0000000000002863 |
| Popis: | Objective: We aimed to analyze the clinical and histopathologic features of cancer-associated myositis (CAM) in relation to anti–transcriptional intermediary factor 1 γ antibody (anti-TIF1-γ-Ab), a marker of cancer association. Methods: We retrospectively studied 349 patients with idiopathic inflammatory myopathies (IIMs), including 284 patients with pretreatment biopsy samples available. For the classification of IIMs, the European Neuromuscular Center criteria were applied. Patients with CAM with (anti-TIF1-γ-Ab[+] CAM) and without anti-TIF1-γ-Ab (anti-TIF1-γ-Ab[−] CAM) were compared with patients with IIM without cancers within and beyond 3 years of myositis diagnosis. Results: Cancer was detected in 75 patients, of whom 36 (48%) were positive for anti-TIF1-γ-Ab. In anti-TIF1-γ-Ab(+) patients with CAM, cancers were detected within 1 year of myositis diagnosis in 35 (97%) and before 1 year of myositis diagnosis in 1. All the anti-TIF1-γ-Ab(+) patients with CAM satisfied the dermatomyositis (DM) criteria, including 2 possible DM sine dermatitis cases, and were characterized histologically by the presence of perifascicular atrophy, vacuolated fibers (VFs), and dense C5b-9 deposits on capillaries (dC5b-9). In contrast, 39 anti-TIF1-γ-Ab(−) patients with CAM were classified into various subgroups, and characterized by a higher frequency of necrotizing autoimmune myopathy (NAM). Notably, all 7 patients with CAM classified into the NAM subgroup were anti-TIF1-γ-Ab(−) and exhibited no dC5b-9 or VFs. Conclusions: CAM includes clinicohistopathologically heterogeneous disease entities. Among CAM entities, anti-TIF1-γ-Ab(+) CAM has characteristically shown a close temporal association with cancer detection and the histopathologic findings of dC5b-9 and VFs, and CAM with NAM is a subset of anti-TIF1-γ-Ab(−) CAM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|